Antibody engineering & therapeutics, the annual meeting of the antibody society December 7–10, 2015, San Diego, CA, USA

References

• Yamada DH, Elsaesser H, Lux A, Timmerman JM, Morrison SL, de la Torre JC, Nimmerjahn F, Brooks DG. Suppression of Fcgamma-receptor-mediated antibody effector function during persistent viral infection. Immunity 2015; 42:379-90; PMID:25680277; http://dx.doi.org/10.1016/j.immuni.2015.01.005
   PubMed Web of Science ®Google Scholar
• Diebolder CA, Beurskens FJ, de Jong RN, Koning RI, Strumane K, Lindorfer MA, Voorhorst M, Ugurlar D, Rosati S, Heck AJ, et al. Complement is activated by IgG hexamers assembled at the cell surface. Science 2014; 343:1260-3; PMID:24626930; http://dx.doi.org/10.1126/science.1248943
   PubMed Web of Science ®Google Scholar
• de Jong RN, Beurskens FJ, Verploegen S, Strumane K, van Kampen MD, Voorhorst M, Horstman W, Engelberts PJ, Oostindie SC, Wang G, et al. A novel platform for the potentiation of therapeutic antibodies based on antigen-dependent formation of IgG hexamers at the cell surface. PLoS Biol 2016; 14:e1002344; PMID:26736041; http://dx.doi.org/10.1371/journal.pbio.1002344
   PubMed Web of Science ®Google Scholar
• Melis JP, Strumane K, Ruuls SR, Beurskens FJ, Schuurman J, Parren PW. Complement in therapy and disease: regulating the complement system with antibody-based therapeutics. Mol Immunol 2015; 67:117-30; PMID:25697848; http://dx.doi.org/10.1016/j.molimm.2015.01.028
   PubMed Web of Science ®Google Scholar
• Baker MP, Reynolds HM, Lumicisi B, Bryson CJ. Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self Nonself 2010; 1:314-22; PMID:21487506; http://dx.doi.org/10.4161/self.1.4.13904
   PubMedGoogle Scholar
• Begley CG, Ellis LM. Drug development: raise standards for preclinical cancer research. Nature 2012; 483:531-3; PMID:22460880; http://dx.doi.org/10.1038/483531a
   PubMed Web of Science ®Google Scholar
• Bradbury A, Pluckthun A. Reproducibility: standardize antibodies used in research. Nature 2015; 518:27-9; PMID:25652980; http://dx.doi.org/10.1038/518027a
   PubMed Web of Science ®Google Scholar
• Bradbury AR, Pluckthun A. Getting to reproducible antibodies: the rationale for sequenced recombinant characterized reagents. Protein Eng Des Sel 2015; 28:303-5; PMID:26446960; http://dx.doi.org/10.1093/protein/gzv051
   PubMed Web of Science ®Google Scholar
• Berglund L, Bjorling E, Oksvold P, Fagerberg L, Asplund A, Szigyarto CA, Persson A, Ottosson J, Wernerus H, Nilsson P, et al. A genecentric Human Protein Atlas for expression profiles based on antibodies. Mol Cell Proteomics 2008; 7:2019-27; PMID:18669619; http://dx.doi.org/10.1074/mcp.R800013-MCP200
   PubMed Web of Science ®Google Scholar
• Bordeaux J, Welsh A, Agarwal S, Killiam E, Baquero M, Hanna J, Anagnostou V, Rimm D. Antibody validation. Biotechniques 2010; 48:197-209; PMID:20359301; http://dx.doi.org/10.2144/000113382
   PubMed Web of Science ®Google Scholar
• Elliott S, Busse L, Bass MB, Lu H, Sarosi I, Sinclair AM, Spahr C, Um M, Van G, Begley CG. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006; 107:1892-5; PMID:16249375; http://dx.doi.org/10.1182/blood-2005-10-4066
   PubMed Web of Science ®Google Scholar
• Freedman LP, Cockburn IM, Simcoe TS. The economics of reproducibility in preclinical research. PLoS Biol 2015; 13:e1002165; PMID:26057340; http://dx.doi.org/10.1371/journal.pbio.1002165
   PubMed Web of Science ®Google Scholar
• Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today 2015; 20:838-47; PMID:25728220; http://dx.doi.org/10.1016/j.drudis.2015.02.008
   PubMed Web of Science ®Google Scholar
• Metz S, Panke C, Haas AK, Schanzer J, Lau W, Croasdale R, Hoffmann E, Schneider B, Auer J, Gassner C, et al. Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing. Protein Eng Des Sel 2012; 25:571-80; PMID:22976197; http://dx.doi.org/10.1093/protein/gzs064
   PubMed Web of Science ®Google Scholar
• Desnoyers LR, Vasiljeva O, Richardson JH, Yang A, Menendez EE, Liang TW, Wong C, Bessette PH, Kamath K, Moore SJ, et al. Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index. Sci Transl Med 2013; 5:207ra144; PMID:24132639; http://dx.doi.org/10.1126/scitranslmed.3006682
   PubMed Web of Science ®Google Scholar
• Wong KR, Menendez E, Craik CS, Kavanaugh WM, Vasiljeva O. In vivo imaging of protease activity by Probody therapeutic activation. Biochimie. 2016 Mar;122:62-7; http://dx.doi.org/10.1016/j.biochi.2015.11.003.
   Google Scholar
• Stefan N, Zimmermann M, Simon M, Zangemeister-Wittke U, Pluckthun A. Novel prodrug-like fusion toxin with protease-sensitive bioorthogonal PEGylation for tumor targeting. Bioconjug Chem 2014; 25:2144-56; PMID:25350699; http://dx.doi.org/10.1021/bc500468s
   PubMed Web of Science ®Google Scholar
• Verdurmen WP, Luginbuhl M, Honegger A, Pluckthun A. Efficient cell-specific uptake of binding proteins into the cytoplasm through engineered modular transport systems. J Control Release 2015; 200:13-22; PMID:25526701; http://dx.doi.org/10.1016/j.jconrel.2014.12.019
   PubMed Web of Science ®Google Scholar
• de Goeij BE, Satijn D, Freitag CM, Wubbolts R, Bleeker WK, Khasanov A, Zhu T, Chen G, Miao D, van Berkel PH, et al. High turnover of tissue factor enables efficient intracellular delivery of antibody-drug conjugates. Mol Cancer Ther 2015; 14:1130-40; PMID:25724665; http://dx.doi.org/10.1158/1535-7163.MCT-14-0798
   PubMed Web of Science ®Google Scholar
• Breij EC, de Goeij BE, Verploegen S, Schuurhuis DH, Amirkhosravi A, Francis J, Miller VB, Houtkamp M, Bleeker WK, Satijn D, et al. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. Cancer Res 2014; 74:1214-26; PMID:24371232; http://dx.doi.org/10.1158/0008-5472.CAN-13-2440
   PubMed Web of Science ®Google Scholar
• Tzeng A, Kwan BH, Opel CF, Navaratna T, Wittrup KD. Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution. Proc Natl Acad Sci U S A 2015; 112:3320-5; PMID:25733854; http://dx.doi.org/10.1073/pnas.1416159112
   PubMed Web of Science ®Google Scholar
• Zhu EF, Gai SA, Opel CF, Kwan BH, Surana R, Mihm MC, Kauke MJ, Moynihan KD, Angelini A, Williams RT, et al. Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. Cancer Cell 2015; 27:489-501; PMID:25873172; http://dx.doi.org/10.1016/j.ccell.2015.03.004
   PubMed Web of Science ®Google Scholar
• Liu X, Pu Y, Cron K, Deng L, Kline J, Frazier WA, Xu H, Peng H, Fu YX, Xu MM. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med 2015; 21:1209-15; PMID:26322579; http://dx.doi.org/10.1038/nm.3931
   PubMed Web of Science ®Google Scholar
• Bronte V. Tumors STING adaptive antitumor immunity. Immunity 2014; 41:679-81; PMID:25517609; http://dx.doi.org/10.1016/j.immuni.2014.11.004
   PubMed Web of Science ®Google Scholar
• Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, Li XD, Mauceri H, Beckett M, Darga T, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 2014; 41:843-52; PMID:25517616; http://dx.doi.org/10.1016/j.immuni.2014.10.019
   PubMed Web of Science ®Google Scholar
• Fan Z, Yu P, Wang Y, Fu ML, Liu W, Sun Y, Fu YX. NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors. Blood 2006; 107:1342-51; PMID:16223768; http://dx.doi.org/10.1182/blood-2005-08-3485
   PubMed Web of Science ®Google Scholar
• Ferris RL. Immunology and immunotherapy of head and neck cancer. J Clin Oncol 2015; 33:3293-304; PMID:26351330; http://dx.doi.org/10.1200/JCO.2015.61.1509
   PubMed Web of Science ®Google Scholar
• Carmi Y, Spitzer MH, Linde IL, Burt BM, Prestwood TR, Perlman N, Davidson MG, Kenkel JA, Segal E, Pusapati GV, et al. Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity. Nature 2015; 521:99-104; PMID:25924063; http://dx.doi.org/10.1038/nature14424
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2016. MAbs 2016, Feb-Mar;8(2):197-204; PMID: 26651519; http://dx.doi.org/10.1080/19420862.2015.1125583
   Web of Science ®Google Scholar
• Moasser MM, Krop IE. The evolving landscape of HER2 targeting in breast cancer. JAMA Oncol 2015; 1:1154-61; PMID:26204261; http://dx.doi.org/10.1001/jamaoncol.2015.2286
   PubMed Web of Science ®Google Scholar
• McCormack PL. Pertuzumab: a review of its use for first-line combination treatment of HER2-positive metastatic breast cancer. Drugs 2013; 73:1491-502; PMID:23982598; http://dx.doi.org/10.1007/s40265-013-0109-0
   PubMed Web of Science ®Google Scholar
• Baron JM, Boster BL, Barnett CM. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. J Oncol Pharm Pract 2015; 21:132-42; PMID:24682654; http://dx.doi.org/10.1177/1078155214527144
   PubMedGoogle Scholar
• Feldmann M, Maini RN. Lasker clinical medical research award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 2003; 9:1245-50; PMID:14520364; http://dx.doi.org/10.1038/nm939
   PubMed Web of Science ®Google Scholar
• Goodall LJ, Ovecka M, Rycroft D, Friel SL, Sanderson A, Mistry P, Davies ML, Stoop AA. Pharmacokinetic and pharmacodynamic characterisation of an anti-mouse TNF receptor 1 domain antibody formatted for in vivo half-life extension. PLoS One 2015; 10:e0137065; PMID:26352810; http://dx.doi.org/10.1371/journal.pone.0137065
   PubMedGoogle Scholar
• McCann FE, Perocheau DP, Ruspi G, Blazek K, Davies ML, Feldmann M, Dean JL, Stoop AA, Williams RO. Selective tumor necrosis factor receptor I blockade is antiinflammatory and reveals immunoregulatory role of tumor necrosis factor receptor II in collagen-induced arthritis. Arthritis Rheumatol 2014; 66:2728-38; PMID:24965881; http://dx.doi.org/10.1002/art.38755
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Spatz A, Robert C. Cutaneous melanoma. Lancet 2014; 383:816-27; PMID:24054424; http://dx.doi.org/10.1016/S0140-6736(13)60802-8
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015; 27:450-61; PMID:25858804; http://dx.doi.org/10.1016/j.ccell.2015.03.001
   PubMed Web of Science ®Google Scholar
• Raedler LA. Opdivo (Nivolumab): second PD-1 inhibitor receives FDA approval for unresectable or metastatic melanoma. Am Health Drug Benefits 2015; 8:180-3; PMID:26629287
   PubMedGoogle Scholar
• Philips GK, Atkins M. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Int Immunol 2015; 27:39-46; PMID:25323844; http://dx.doi.org/10.1093/intimm/dxu095
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Mazieres J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 2015; 16:257-65; PMID:25704439; http://dx.doi.org/10.1016/S1470-2045(15)70054-9
   PubMed Web of Science ®Google Scholar
• Pluckthun A. Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy. Annu Rev Pharmacol Toxicol 2015; 55:489-511; PMID:25562645; http://dx.doi.org/10.1146/annurev-pharmtox-010611-134654
   PubMed Web of Science ®Google Scholar
• Wurch T, Pierre A, Depil S. Novel protein scaffolds as emerging therapeutic proteins: from discovery to clinical proof-of-concept. Trends Biotechnol 2012; 30:575-82; PMID:22944617; http://dx.doi.org/10.1016/j.tibtech.2012.07.006
   PubMed Web of Science ®Google Scholar
• Cooke RM, Brown AJ, Marshall FH, Mason JS. Structures of G protein-coupled receptors reveal new opportunities for drug discovery. Drug Discov Today 2015; 20:1355-64; PMID:26303408; http://dx.doi.org/10.1016/j.drudis.2015.08.003
   PubMed Web of Science ®Google Scholar
• Errey JC, Dore AS, Zhukov A, Marshall FH, Cooke RM. Purification of stabilized GPCRs for structural and biophysical analyses. Methods Mol Biol 2015; 1335:1-15; PMID:26260590; http://dx.doi.org/10.1007/978-1-4939-2914-6_1
   PubMedGoogle Scholar
• Hutchings CJ, Cseke G, Osborne G, Woolard J, Zhukov A, Koglin M, Jazayeri A, Pandya-Pathak J, Langmead CJ, Hill SJ, et al. Monoclonal anti-beta1-adrenergic receptor antibodies activate G protein signaling in the absence of beta-arrestin recruitment. MAbs 2014; 6:246-61; PMID:24253107; http://dx.doi.org/10.4161/mabs.27226
   PubMed Web of Science ®Google Scholar
• Bankert KC, Oxley KL, Smith SM, Graham JP, de Boer M, Thewissen M, Simons PJ, Bishop GA. Induction of an altered CD40 signaling complex by an antagonistic human monoclonal antibody to CD40. J Immunol 2015; 194:4319-27; PMID:25795759; http://dx.doi.org/10.4049/jimmunol.1402903
   PubMed Web of Science ®Google Scholar
• de Vos AF, Melief MJ, van Riel D, Boon L, van Eijk M, de Boer M, Laman JD. Antagonist anti-human CD40 antibody inhibits germinal center formation in cynomolgus monkeys. Eur J Immunol 2004; 34:3446-55; PMID:15517614; http://dx.doi.org/10.1002/eji.200424973
   PubMed Web of Science ®Google Scholar
• Alabraba EB, Lai V, Boon L, Wigmore SJ, Adams DH, Afford SC. Coculture of human liver macrophages and cholangiocytes leads to CD40-dependent apoptosis and cytokine secretion. Hepatology 2008; 47:552-62; PMID:17999420; http://dx.doi.org/10.1002/hep.22011
   PubMed Web of Science ®Google Scholar
• Jones TD, Carter PJ, Pluckthun A, Vasquez M, Holgate RG, Hotzel I, Popplewell AG, Parren PW, Enzelberger M, Rademaker HJ, et al. The INNs and outs of antibody nonproprietary names. MAbs 2016; 8:1-9; PMID:26716992; http://dx.doi.org/10.1080/19420862.2015.1114320
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhu M, Yu P, Fu YX. Promoting immune responses by LIGHT in the face of abundant regulatory T cell inhibition. J Immunol 2010; 184:1589-95; PMID:20042587; http://dx.doi.org/10.4049/jimmunol.0901582
   PubMed Web of Science ®Google Scholar
• WHO-INN. International nonproprietary names (INN) for biological and biotechnological substances 2014 (http://www.who.int/medicines/services/inn/BioRev2014.pdf).
   Google Scholar
• WHO-INN. International Nonproprietary Names (http://www.who.int/medicines/services/inn/en/).
   Google Scholar
• AMA. Application Forms [Internet]. Chicago (IL). [cited 2016 Feb 5]. Available from http://www.ama-assn.org/ama/pub/physician-resources/medical-science/united-states-adopted-names-council/application-forms.page?
   Google Scholar
• AMA. Application Forms [Internet]. Chicago (IL). [cited 2016 Feb 5]. Available from http://www.ama-assn.org/ama/pub/physician-resources/medical-science/united-states-adopted-names-council.page?
   Google Scholar
• Scheepers C, Shrestha RK, Lambson BE, Jackson KJ, Wright IA, Naicker D, Goosen M, Berrie L, Ismail A, Garrett N, et al. Ability to develop broadly neutralizing HIV-1 antibodies is not restricted by the germline Ig gene repertoire. J Immunol 2015; 194:4371-8; PMID:25825450; http://dx.doi.org/10.4049/jimmunol.1500118
   PubMed Web of Science ®Google Scholar